Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Atazanavir Sulfate

FDA-approved product (capsule, oral), marketed as Atazanavir Sulfate, Reyataz.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Atazanavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE08

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli48.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Atazanavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Atazanavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women

    NCT01705574 · start 2012-10-24

    Registered record
    Registry ID
    NCT01705574
    Conditions
    Acquired Immunodeficiency Syndrome; HIV Infections
    Interventions
    E/C/F/TDF; ATV; RTV; FTC/TDF; E/C/F/TDF Placebo; ATV Placebo; RTV Placebo; FTC/TDF Placebo; E/C/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10-24
    Completion
    2018-09-06
    Enrolment
    583

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immunodeficiency Syndrome; HIV Infections
    InterventionE/C/F/TDF; ATV; RTV; FTC/TDF +5 more
    PhasePhase 3
    Registry statusCompleted

  • Antiretroviral Therapy and Extreme Weight

    NCT01805427 · start 2012-09

    Registered record
    Registry ID
    NCT01805427
    Conditions
    HIV Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-09
    Completion
    2013-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • A Study to Treat Subjects With Telaprevir, Ribavirin, and Peginterferon Who Are Coinfected With HIV and Hepatitis C Virus (HCV)

    NCT01467479 · start 2011-12

    Registered record
    Registry ID
    NCT01467479
    Conditions
    Hepatitis C
    Interventions
    Telaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2011-12
    Completion
    2014-02
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis C
    InterventionTelaprevir; Ribavirin; Pegylated Interferon Alfa-2a; Highly Active Antiretroviral Therapy (HAART)
    PhasePhase 3
    Registry statusTerminated

  • Atazanavir/Ritonavir and Zinc Pharmacokinetic Study

    NCT01475227 · start 2011-12

    Registered record
    Registry ID
    NCT01475227
    Conditions
    HIV Infection
    Interventions
    1 Solvazinc tablet, day 2 to day 15; 1 Solvazinc tablet, day 15 to day 28
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-12
    Completion
    2012-03
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    Intervention1 Solvazinc tablet, day 2 to day 15; 1 Solvazinc tablet, day 15 to day 28
    PhasePhase 4
    Registry statusCompleted

  • A Drug-Drug Interaction Study of Ketoconazole, Rifampicin and Ritonavir-Boosted Atazanavir With Single-Dose RO5093151 in Healthy Volunteers

    NCT01591850 · start 2011-09

    Registered record
    Registry ID
    NCT01591850
    Conditions
    Healthy Volunteer
    Interventions
    RO5093151; atazanavir; ketoconazole; rifampicin; ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2011-11
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteer
    InterventionRO5093151; atazanavir; ketoconazole; rifampicin +1 more
    PhasePhase 1
    Registry statusCompleted

  • Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

    NCT01389310 · start 2011-07

    Registered record
    Registry ID
    NCT01389310
    Conditions
    HIV Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2011-07
    Completion
    2014-02
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Switching From Efavirenz to Atazanavir/ Ritonavir in HIV-infected Subjects With Good Virologic Suppression

    NCT01194856 · start 2010-10

    Registered record
    Registry ID
    NCT01194856
    Conditions
    HIV Infection; Mitochondrial Dysfunction
    Interventions
    Atazanavir/ritonavir; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2010-10
    Completion
    2011-12
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Mitochondrial Dysfunction
    InterventionAtazanavir/ritonavir; Efavirenz
    PhasePhase 4
    Registry statusTerminated

  • Safety Study of Raltegravir in HIV/HCV Co-infected Patients

    NCT01225705 · start 2010-10

    Registered record
    Registry ID
    NCT01225705
    Conditions
    HIV; Hepatitis C
    Interventions
    raltegravir; Atazanavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2010-10
    Completion
    2012-08
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Hepatitis C
    Interventionraltegravir; Atazanavir/ritonavir
    PhasePhase 4
    Registry statusWithdrawn

  • Efficacy of Atazanavir/Ritonavir Monotherapy as Maintenance in Patients With Viral Suppression

    NCT01511809 · start 2010-09

    Registered record
    Registry ID
    NCT01511809
    Conditions
    HIV-1 Infection
    Interventions
    Atazanavir/ritonavir monotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-09
    Completion
    2015-05
    Enrolment
    117

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionAtazanavir/ritonavir monotherapy
    PhasePhase 3
    Registry statusCompleted

  • Atazanavir/Ritonavir and Darunavir/Ritonavir PK Tail Study

    NCT01073761 · start 2010-04

    Registered record
    Registry ID
    NCT01073761
    Conditions
    HIV; HIV Infections
    Interventions
    darunavir/ritonavir then atazanavir/ritonavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; HIV Infections
    Interventiondarunavir/ritonavir then atazanavir/ritonavir
    PhasePhase 1
    Registry statusCompleted

  • Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

    NCT00943540 · start 2009-07

    Registered record
    Registry ID
    NCT00943540
    Conditions
    HIV Infection; HIV Infections
    Interventions
    raltegravir QD; atazanavir; lamivudine (or emtricitabine)
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-07
    Completion
    2011-01
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; HIV Infections
    Interventionraltegravir QD; atazanavir; lamivudine (or emtricitabine)
    PhasePhase 2
    Registry statusCompleted

  • Pilot Study of a Raltegravir Based NRTI Sparing Regimen

    NCT00814879 · start 2009-05

    Registered record
    Registry ID
    NCT00814879
    Conditions
    Acquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
    Interventions
    Raltegravir; Atazanavir; Standard treatment regimen
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-05
    Completion
    2013-11
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcquired Immune Deficiency Syndrome; AIDS; Human Immunodeficiency Virus; HIV Infections
    InterventionRaltegravir; Atazanavir; Standard treatment regimen
    PhaseNot applicable
    Registry statusCompleted

  • Atazanavir and Lamivudine for Treatment Simplification

    NCT00885482 · start 2009-05

    Registered record
    Registry ID
    NCT00885482
    Conditions
    HIV Infections
    Interventions
    Lamiduvine (Epivir); Atazanavir (Reyataz); Ritonavir (Norvir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-05
    Completion
    2011-05
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionLamiduvine (Epivir); Atazanavir (Reyataz); Ritonavir (Norvir)
    PhasePhase 4
    Registry statusCompleted

  • The Effects of Atazanavir-induced Hyperbilirubinemia During Human Endotoxemia

    NCT00916448 · start 2009-05

    Registered record
    Registry ID
    NCT00916448
    Conditions
    Endotoxemia; Inflammation; Multi Organ Dysfunction Syndrome; Sepsis
    Interventions
    Atazanavir; E. coli endotoxin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2009-05
    Completion
    2015-07
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndotoxemia; Inflammation; Multi Organ Dysfunction Syndrome; Sepsis
    InterventionAtazanavir; E. coli endotoxin
    PhaseNot applicable
    Registry statusCompleted

  • A Pilot Study Of A Novel Treatment Regimen, Maraviroc + Ritonavir Boosted Atazanavir, In Treatment Naive HIV-Infected Patients

    NCT00827112 · start 2009-03

    Registered record
    Registry ID
    NCT00827112
    Conditions
    Human Immunodeficiency Virus-1
    Interventions
    maraviroc; maraviroc
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-03
    Completion
    2011-07
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHuman Immunodeficiency Virus-1
    Interventionmaraviroc; maraviroc
    PhasePhase 2
    Registry statusCompleted